SuperworthKORU Medical Systems KRMD
- Market cap
- $146.4M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 3.2×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $45.1M
- +22% on a year ago
- Net margin
- −4.0%
- Free cash flow yield
- 0.5%
KORU Medical Systems trades at 3.2× sales. Its trailing earnings are negative, so it has no PE. Revenue was $45.1M over the last twelve months, up 22% on a year earlier with a −4% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $7M−10% | $7.2M−2% | $8.2M+11% | $8.4M+22% | $8.2M+17% | $8.8M+23% | $9.6M+18% | $10.2M+21% | $10.4M+27% | $10.9M+23% | $11.8M+22% | $12M+18% | |
| Cost of revenue | $2.7M−23% | $2.9M−13% | $3.1M−5% | $3M−3% | $3M+13% | $3.3M+15% | $3.6M+16% | $3.7M+26% | $4.1M+38% | $4.1M+25% | $4.5M+26% | $4.2M+13% |
| Gross profit | $4.3M+1% | $4.3M+6% | $5.1M+23% | $5.5M+41% | $5.2M+19% | $5.6M+28% | $6M+19% | $6.5M+18% | $6.3M+21% | $6.8M+23% | $7.2M+20% | $7.8M+21% |
| R&D | $1.3M+50% | $1.3M−22% | $1.5M−6% | $1.1M−29% | $1.5M+19% | $1.1M−14% | $1.1M−25% | $1.2M+5% | $933.1K−39% | $1.1M+3% | $1.3M+18% | $1.1M−11% |
| SG&A | $4.6M−4% | $5M+5% | $5.4M−1% | $5.3M+0% | $5.1M+11% | $5.8M+16% | $6M+11% | $5.4M+1% | $6M+17% | $6M+4% | $6.6M+11% | $5.9M+10% |
| −$1.8M+17% | −$2.2M−13% | −$2M−36% | −$1.2M−63% | −$1.7M−5% | −$1.6M−28% | −$1.2M−37% | −$312.7K−74% | −$867.7K−49% | −$547.1K−66% | −$864.9K−31% | $627K | |
| Interest expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pre-tax income | −$1.7M+12% | −$2M−16% | −$1.9M−35% | −$988.7K−68% | −$1.6M−5% | −$1.6M−23% | −$1.2M−40% | −$189.5K−81% | −$778.1K−51% | −$482.2K−69% | −$807.1K−31% | $258.2K |
| −$300.2K+11% | $5.4M | n/a | n/a | n/a | n/a | n/a | $17.4K | −$150 | $4.7K | n/a | $5.8K−67% | |
| Net income | −$1.4M+12% | −$7.5M+278% | −$1.9M−20% | −$988.7K−60% | −$1.6M+16% | −$1.6M−79% | −$1.2M−40% | −$206.9K−79% | −$778K−51% | −$486.9K−69% | −$807.1K−31% | $252.4K |
| −$0.03+0% | −$0.16+300% | $0.04 | $0.02 | $0.03 | −$0.03−81% | −$0.03 | $0.00 | $0.02−33% | −$0.01−67% | −$0.02−33% | $0.01 | |
| 45.6M+1% | 45.7M+1% | 45.7M+1% | 45.8M+0% | 45.9M+1% | 45.8M+0% | 46M+1% | 46.2M+1% | 46.2M+1% | 46.3M+1% | 46.4M+1% | 49.5M+7% |
Revenue: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them. 17 periods, Q2 FY11 to Q3 FY15: not printed by the filing, worked out from its own lines.
R&D: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
SG&A: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
Operating income: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
Income tax: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
Net income: Q1 FY11 and Q1 FY12: 6 months less the 3 months printed beside them.
EPS, diluted: 32 periods, Q1 FY11 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY11: share-days: the 6-month average less the second quarter's. Q2 FY11 and Q3 FY11: not printed by the filing, worked out from its own lines. Q4 FY11: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution. 6 periods, Q4 FY12 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days. 8 periods, Q4 FY17 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest KORU Medical Systems' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| KRMDKORU Medical Systems | $146.4M | n/m | 149× | 3.2× | +22% | −4.0% | |
| PDEXPro DEX | $199.3M | 15.1× | 16.6× | 2.6× | +16% | 17.6% | |
| KEQUKewaunee Scientific | $94.9M | 11.9× | 13.7× | 0.3× | +5% | 3.0% | |
| UTMDUtah Medical Products | $236.3M | 22.6× | 20.9× | 6.5× | −7% | 29.0% | |
| INFUInfuSystem | $277.6M | 34.0× | 43.5× | 1.9× | +2% | 6.0% | |
| APTAlpha Pro Tech | $56.7M | 13.6× | 14.8× | 0.9× | +6% | 6.8% | |
| EMBCEmbecta | $380.2M | 4.6× | 11.7× | 0.4× | −8% | 8.6% | |
| TCMDTactile Systems Technology | $535.5M | 21.9× | 62.9× | 1.5× | +17% | 7.1% | |
| NEPHNephros | $38.3M | 22.1× | 28.4× | 1.9× | +24% | 8.4% | |
| MDXGMimedx | $569.9M | 97.8× | 21.1× | 1.6× | −2% | 1.8% | |
| MOVMovado | $701.9M | 17.5× | 13.3× | 1.0× | +5% | 6.0% | |
| Peer median | $257M | 19.7× | 18.7× | 1.6× | +5% | 6.9% |
More on KORU Medical Systems
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .